News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter
Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

Celebrities and Cancer
Immune Oncology
Breast Oncology
Gastrointestinal Oncology
Lung Oncology
Radiotherapy
Cancer Types
Science
Trial Updates
ASCO
ESMO
ESO
MASCC
Cancer Center Near Me
Oncologist Near Me
OncoDaily Party 2025

Childhood Cancer
Health Policy
Hall of Fame
OncoIndustry
Public Health
Oncology Tech
Blog Posts
BIGR
Global Cancer Movement
History
Oncolibrary
OncoThon 2025
Yvonne Award 2025

Apr / 2026

April 2026
M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

« Mar

OncoDaily IO OncoDaily GI Hemostasis Today Fertility News

Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

News Feed
OncoDaily Pulse
OncoGrants
OncoDaily TV
NewsLetter

Tedros Adhanom Ghebreyesus: Inspiring Meeting with the First Lady of Uzbekistan on Childhood Cancer Control

Tedros Adhanom Ghebreyesus: Inspiring Meeting with the First Lady of Uzbekistan on Childhood Cancer Control

Highlights from AACR 2026 Part 3

Highlights from AACR 2026 Part 3

Myelo 2026: Virtual Global Congress on Multiple Myeloma

Myelo 2026: Virtual Global Congress on Multiple Myeloma

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition

New ESMO Consensus Driven Document Defines Lines of Therapy Across Solid Tumours

New ESMO Consensus Driven Document Defines Lines of Therapy Across Solid Tumours

Heber Reyes: Congratulations to the Entire Team of IMDC on a New Article On Metastatic Renal Cell Carcinoma

Heber Reyes: Congratulations to the Entire Team of IMDC on a New Article On Metastatic Renal Cell Carcinoma

Grand Rounds by OncoDaily: AI in Oncology Edition

Grand Rounds by OncoDaily: AI in Oncology Edition

FDA Priority Review: Pembrolizumab + Enfortumab Vedotin for Cisplatin-Eligible MIBC

FDA Priority Review: Pembrolizumab + Enfortumab Vedotin for Cisplatin-Eligible MIBC

OncoCalendar

This event has passed.

ESGO

Apr 23 • 2:28 AM

Google Calendar
iCalendar
Outlook 365
Outlook Live

Details

Date: Apr 23, 2026
Time:
2:28 AM

Organizer

CancerWorld OncoDaily Medical Journal Hemostasis Today OncoDaily IO OncoDaily GI OncoDailyTV

OncoDaily™ | © 2023 - 2025

All rights reserved. Unauthorized reproduction, distribution, or transmission of any content on OncoDaily.com is strictly prohibited. For permission requests or inquiries, please contact OncoDaily directly. By accessing and using OncoDaily.com, you acknowledge and agree to comply with this copyright notice, as well as our Privacy Policy, Editorial Policy, Cookie Policy, and Disclaimer. Continued use of this website constitutes acceptance of all such terms and policies.

Phone number: +1 978 717 48 84

Email: info@oncodaily.com

About Privacy Policy Editorial Policy Cookie Policy Disclaimer

Crafted by Matemat

Oncology OncoDaily cancer Breast Cancer fight against cancer Global fight against cancer cancer care ASCO Lung cancer Cancer research Headlines ESMO immunotherapy NSCLC MD Anderson Cancer Center cancer treatment cancer awareness Research colorectal cancer ASCO24 Childhood Cancer AACR clinical trials prostate cancer FDA UICC Dana-Farber Cancer Institute American Cancer Society European Cancer Organisation SIOP chemotherapy Robert Orlowski Pancreatic Cancer Myeloma NCI Myeloma Paper of the Day American Society of Clinical Oncology Vivek Subbiah National Cancer Institute Paolo Tarantino AI radiation oncology cervical cancer healthcare IASLC WHO Memorial Sloan Kettering Cancer Center multiple myeloma ASCO25 Zainab Shinkafi-Bagudu

European School of Oncology

Sitemap

Hemostasis Today

Fertility News

Oncodaily Journal

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}